242 related articles for article (PubMed ID: 23547660)
1. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.
Wise RA; Anzueto A; Calverley P; Dahl R; Dusser D; Pledger G; Koenen-Bergmann M; Joseph E; Cotton D; Disse B
Respir Res; 2013 Apr; 14(1):40. PubMed ID: 23547660
[TBL] [Abstract][Full Text] [Related]
2. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
3. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
5. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
[TBL] [Abstract][Full Text] [Related]
6. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
Dahl R; Kaplan A
BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
Ichinose M; Fujimoto T; Fukuchi Y
Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
[TBL] [Abstract][Full Text] [Related]
10. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
[TBL] [Abstract][Full Text] [Related]
11. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
Caillaud D; Le Merre C; Martinat Y; Aguilaniu B; Pavia D
Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.
Wise R; Calverley PM; Dahl R; Dusser D; Metzdorf N; Müller A; Fowler A; Anzueto A
NPJ Prim Care Respir Med; 2015 Nov; 25():15067. PubMed ID: 26540491
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
[TBL] [Abstract][Full Text] [Related]
14. TIOtropium Safety and Performance In Respimat
Zhong N; Moon HS; Lee KH; Mahayiddin AA; Boonsawat W; Isidro MG; Bai C; Mueller A; Metzdorf N; Anzueto A
Respirology; 2016 Nov; 21(8):1397-1403. PubMed ID: 27490162
[TBL] [Abstract][Full Text] [Related]
15. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR
Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
[TBL] [Abstract][Full Text] [Related]
16. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC
Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.
Keating GM
Drugs; 2014 Oct; 74(15):1801-16. PubMed ID: 25300412
[TBL] [Abstract][Full Text] [Related]
18. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941
[TBL] [Abstract][Full Text] [Related]
19. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease: systematic review].
Cai HD; Hou J; Lyu YN; Xiong L; Lu MZ; Wu SL
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Aug; 40(8):596-603. PubMed ID: 28810313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
